CNTA 16.05 (+1.52%)
US1523091007BiotechnologyBiotechnology

Centessa Pharmaceuticals (CNTA) Stock Highlights

16.05 | +1.52%
2024-10-21 01:58:37
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.

Statistics

Range Today
15.51 16.47
Volume Today 392.1K
Range 1 Year
5.58 17.59
Volume 1 Year 88.77M
Range 3 Year
2.88 17.73
Volume 3 Year 176.07M
Range 10 Year
2.88 26.9
Volume 10 Year 199.58M

Highlights

Market Capitalization 2.06B (mid)
Floating Shares 76.16M
Current Price 16.05
Price To Earnings -10.17
Price To Revenue 234.86
Price To Book 6.33
Earnings Per Share -1.55
Payout Ratio 0%

Performance

Latest +1.52%
1 Month +0.38%
3 Months +64.45%
6 Months +50.28%
1 Year +147.69%
3 Years -4.46%
5 Years -20.74%
10 Years -20.74%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.